Phase II funding will be used for pre-clinical assessment of regenerative cartilage therapy Follows Phase I SBRI funding, announced in April 2019 Cambridge, UK, 28 January 2020 Mogrify Ltd (Mogrify™), a UK company aiming to transform the development of cell therapies, today announced that it has secured $1.1M of additional funding from SBRI Healthcare, the NHS […]Read More
Oxford Drug Design (ODD) wins major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures totalling over £8m to develop new antibiotics effective against drug-resistant superbugs and to expand its proprietary machine learning computational platform. Oxford, UK, 18th June, 2019 – Oxford Drug […]Read More
Healthcare to advance regenerative cartilage therapy to the clinic Chondrogenix will use Mogrify’s data-driven conversion platform to generate a safe, efficient and scalable source of cartilage cells for the treatment of osteoarthritis Cambridge, UK, 1 st April 2019: Chondrogenix, a wholly owned subsidiary of Mogrify Ltd (Mogrify), a UK company aiming to transform the future […]Read More
